Monitoring of gene expression in tacrolimus-treated de novo renal allograft recipients facilitates individualized immunosuppression : results of the IMAGEN study
Sommerer, Claudia (Heidelberg University Hospital (Alemanya))
Brunet, M. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Budde, K. (Charité University Hospital Berlin)
Millán, O. (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Guirado, Luis (Institut d'Investigació Biomèdica Sant Pau)
Glander, P. (Charité University Hospital Berlin)
Meuer, S. (Institute of Immunology. University Hospital Heidelberg)
Zeier, M. (Heidelberg University Hospital (Alemanya))
Giese, Thomas (Heidelberg University Hospital (Alemanya))

Data:	2021
Resum:	Aims: Calcineurin inhibitors (CNI) have a small therapeutic window, and drug monitoring is required. Pharmacokinetic monitoring does not correlate sufficiently with clinical outcome. Therefore, the expression of nuclear factor of activated T cells (NFAT)-regulated genes in the peripheral blood has been suggested as a potentially useful immune monitoring tool to optimize CNI therapy. NFAT-regulated gene expression (RGE) was evaluated in renal allograft recipients as predictive biomarker to detect patients at risk of acute rejection or infections. Methods: NFAT-RGE (interleukin-2, interferon-γ, granular-macrophage colony-stimulating factor) was evaluated by quantitative real-time polymerase chain reaction in whole blood samples at day 7, day 14, month 1, 3, and 6 after transplantation in 64 de novo renal allograft recipients from 3 European centres. Immunosuppression consisted of tacrolimus (Tac), mycophenolic acid, and corticosteroids. Results: Tac concentrations (C0 and C1. 5) correlated inversely with NFAT-RGE (P <. 01). NFAT-RGE showed a high interindividual variability (1-61%). Patients with high residual gene expression (NFAT-RGE ≥30%) were at the increased risk of acute rejection in the following months (35 vs. 5%, P =. 02), whereas patients with low residual gene expression (NFAT-RGE <30%) showed a higher incidence of viral complications, especially cytomegalovirus and BK virus replication (52. 5 vs. 10%, P =. 01). Conclusions: NFAT-RGE was confirmed as a potential noninvasive early predictive biomarker in the immediate post-transplant period to detect patients at risk of acute rejection and infectious complications in Tac-treated renal allograft recipients. Monitoring of NFAT-RGE may provide additional useful information for physicians to achieve individualized Tac treatment.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Biomarker ; Cytomegalovirus ; Pharmacodynamics ; Pharmacokinetics ; Rejection ; Renal transplantation ; Tacrolimus
Publicat a:	British Journal of Clinical Pharmacology, Vol. 87 Núm. 10 (october 2021) , p. 3851-3862, ISSN 1365-2125

DOI: 10.1111/bcp.14794
PMID: 33620734

12 p, 2.3 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats